27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
- Protagonist Therapeutics Inc (NASDAQ:PTGX) announced topline results from its collaboration with Janssen Biotech Inc, a part of Johnson & Johnson (NYSE:JNJ), in the FRONTIER 1 Phase 2b trial of oral Interleukin-23 receptor (IL-23R) antagonist peptide JNJ-2113 in patients with moderate-to-severe plaque psoriasis.
- Data from the 255-patient study showed that JNJ-2113 achieved the study's primary efficacy endpoint, with a statistically significant greater proportion of patients achieving PASI-75 (a 75% improvement in skin lesions as measured by the Psoriasis Area and Severity Index) responses compared to placebo at Week 16 in all five treatment groups.
- A clear dose-response was observed across an eight-fold dose range. Treatment was well tolerated, with no meaningful difference in the frequency of adverse events across treatment groups versus placebo.
- Data will be presented from various pre-clinical and clinical studies on JNJ-2113 at medical conferences beginning in the second quarter of 2023.
- JNJ-2113 (formerly PN-235) was discovered and is being developed under the license and collaboration agreement between Protagonist and Janssen Biotech.
- Protagonist completed a Phase 1 study of JNJ-2113 in healthy volunteers in October 2021.
- Janssen retains exclusive, worldwide rights to develop in Phase 2 and beyond and commercialize compounds derived from the research conducted under the agreement against a broad range of indications.
- Price Action: PTGX shares are up 15.20% at $17.51 on the last check Tuesday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!